Abstract
Phosphodiesterases (PDEs), as key regulators of cyclic nucleotides, and their inhibitors have been emerged as new pharmacological targets and promising drug candidates for many diseases, including central nervous system pathologies. The high level of PDE10A expression in the striatal medium spiny neurons suggests a prominent function role for the isoenzyme. Basal ganglia dysfunction is associated with neuropsychiatric disorders and until recently the development of PDE10A inhibitors has been focused on schizophrenia. Currently, the pharmaceutical research on PDE10A inhibitors is moving to show the modulation of other functions associated with the basal ganglia such the motor control. Thus, PDE10A inhibitors may be important pharmacological agents for neurodegenerative disorders such as Parkinson’s and Huntington’s diseases. Recent data supporting new clues for PDE10A as therapeutic target together with a concise review of the chemical structures of its inhibitors are provided here. The goal of this manuscript is to provide new ideas for assistant pharmacologist and medicinal chemists in the search for PDE10A inhibitors as new disease modifying drugs for Parkinson’s disease.
Keywords: cAMP, drug design, neurodegenerative diseases, Parkinson’s disease, PDE10A inhibitors.
Current Medicinal Chemistry
Title:Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Volume: 21 Issue: 10
Author(s): A.M. Garcia, M. Redondo, A. Martinez and C. Gil
Affiliation:
Keywords: cAMP, drug design, neurodegenerative diseases, Parkinson’s disease, PDE10A inhibitors.
Abstract: Phosphodiesterases (PDEs), as key regulators of cyclic nucleotides, and their inhibitors have been emerged as new pharmacological targets and promising drug candidates for many diseases, including central nervous system pathologies. The high level of PDE10A expression in the striatal medium spiny neurons suggests a prominent function role for the isoenzyme. Basal ganglia dysfunction is associated with neuropsychiatric disorders and until recently the development of PDE10A inhibitors has been focused on schizophrenia. Currently, the pharmaceutical research on PDE10A inhibitors is moving to show the modulation of other functions associated with the basal ganglia such the motor control. Thus, PDE10A inhibitors may be important pharmacological agents for neurodegenerative disorders such as Parkinson’s and Huntington’s diseases. Recent data supporting new clues for PDE10A as therapeutic target together with a concise review of the chemical structures of its inhibitors are provided here. The goal of this manuscript is to provide new ideas for assistant pharmacologist and medicinal chemists in the search for PDE10A inhibitors as new disease modifying drugs for Parkinson’s disease.
Export Options
About this article
Cite this article as:
Garcia A.M., Redondo M., Martinez A. and Gil C., Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?, Current Medicinal Chemistry 2014; 21 (10) . https://dx.doi.org/10.2174/0929867321666131228221749
DOI https://dx.doi.org/10.2174/0929867321666131228221749 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Multiple Roles of the Extracellular Matrix in Inflammation
Current Pharmaceutical Design Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Human Embryonic Stem Cell Therapies for Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Regulation of Insulin Release at Pre-exocytotic Stages of the Secretory Process
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology Alzheimer’s Disease Amyloid Peptides Interact with DNA, As Proved by Surface Plasmon Resonance
Current Alzheimer Research Therapeutic Potential of Nucleic Acid-Based Drugs in Coronary Hyper- Proliferative Vascular Diseases
Current Medicinal Chemistry Link of COVID-19 and Neurodegenerative Disorders
CNS & Neurological Disorders - Drug Targets Computer Aided Systems for Diabetic Retinopathy Detection Using Digital Fundus Images: A Survey
Current Medical Imaging Modulation of the Intrinsic Properties of Motoneurons by Serotonin
Current Pharmaceutical Design Treatment of Catatonia with Asenapine in a Patient with Schizotypal Personality Disorder, Psychotic Depression and Septic Shock from SARSCoV- 2 - A Case Report
CNS & Neurological Disorders - Drug Targets Astrocytes: Adhesion Molecules and Immunomodulation
Current Drug Targets Lipid Composition of Cell Membranes and Its Relevance in Type 2 Diabetes Mellitus
Current Diabetes Reviews Directed Functional Connectivity of Posterior Cingulate Cortex and Whole Brain in Alzheimer's Disease and Mild Cognitive Impairment
Current Alzheimer Research Using Photoinduced Charge Transfer Reactions to Study Conformational Dynamics of Biopolymers at the Single-Molecule Level
Current Pharmaceutical Biotechnology Peptide Self-Assemblies for Drug Delivery
Current Topics in Medicinal Chemistry Role of the Osteochondral Unit in the Pathogenesis of Osteoarthritis: Focus on the Potential Use of Clodronate
Current Rheumatology Reviews The Effect of Cannabis on Perception of Time: A Critical Review
Current Pharmaceutical Design Effects of Leptin on Biliary Lipids: Potential Consequences for Gallstone Formation and Therapy in Obesity
Current Drug Targets - Immune, Endocrine & Metabolic Disorders